Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study

Teriflunomide is a once-daily oral immunomodulator approved for the treatment of relapsing–remitting multiple sclerosis. This post hoc analysis of the Phase III TOWER study evaluated the effects of teriflunomide treatment on five severe relapse outcomes: relapses with sequelae defined by an increase...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Miller, Aaron E., Macdonell, Richard, Comi, Giancarlo, Freedman, Mark S., Kappos, Ludwig, Mäurer, Mathias, Olsson, Tomas P., Wolinsky, Jerry S., Bozzi, Sylvie, Dive-Pouletty, Catherine, O’Connor, Paul W.
Formato: Artigo
Idioma:Inglês
Publicado em: Springer Berlin Heidelberg 2014
Assuntos:
Original Communication
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4155167/
https://ncbi.nlm.nih.gov/pubmed/24972678
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00415-014-7395-7
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados